# OnCo record paper-egfr-nsclc-lancet-oncol-2012 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-egfr-nsclc-lancet-oncol-2012/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-egfr-nsclc-lancet-oncol-2012" ;
  schema:name "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial"@en ;
  schema:description "Phase 2 or 3 results paper on EGFR in Non-small-cell lung cancer, in The Lancet Oncology (2012), one of the most cited Europe PMC records with EGFR in its title."@en ;
  schema:url <https://onco.cc/key-papers/paper-egfr-nsclc-lancet-oncol-2012/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s1470-2045(11)70393-x>, <https://pubmed.ncbi.nlm.nih.gov/22285168/>, <https://europepmc.org/article/MED/22285168> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s1470-2045(11)70393-x> ;
  schema:datePublished "2012"^^xsd:gYear ;
  schema:author "Rosell R, Carcereny E, Gervais R, et al." ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .